{
    "nctId": "NCT00237627",
    "briefTitle": "Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer",
    "officialTitle": "A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil\u00ae) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 107,
    "primaryOutcomeMeasure": "Maximum tolerated dose (MTD) of PS-341 in combination with Doxil (Phase I)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nPhase I (closed to accrual as of 10/15/2007)\n\n* Histologically or cytologically confirmed solid tumor or hematologic malignancy, including, but not limited to, any of the following:\n\n  * Breast cancer\n  * Ovarian cancer\n  * Myeloid or lymphoid leukemia\n  * Hodgkin or non-Hodgkin lymphoma\n  * Multiple myeloma\n* Measurable or evaluable disease\n* Must meet 1 of the following criteria:\n\n  * Refractory to at least one prior conventional treatment regimen\n  * Not a candidate for conventional therapy\n  * No conventional therapy exists\n* No clinically or radiographically significant pleural or pericardial effusion\n\n  * Patients with ascites may be eligible at the discretion of the investigator\n* Previously treated central nervous system disease allowed provided it has been stable for \\> 3 months and it is not the only site of measurable disease\n* Not eligible for a higher priority protocol\n\nPhase II\n\n* Diagnosis of breast cancer\n\n  * Metastatic disease\n* Measurable disease by RECIST criteria\n* No symptomatic brain metastases\n\n  * Patients with treated brain metastases that have been stable for \\> 3 months and does not require chronic steroids are eligible\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\nPhase I (closed to accrual as of 10/15/2007)\n\n* Karnofsky performance status 60-100%\n* Life expectancy \u2265 2 months\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* WBC \u2265 2,000/mm\u00b3\n* ANC \u2265 1,500/mm\u00b3 (\u2265 1,000/mm\u00b3 for patients with marrow infiltration)\n* Platelet count \u2265 100,000/mm\u00b3 (\u2265 50,000/mm\u00b3 for patients with marrow infiltration)\n* Hemoglobin \u2265 8 g/dL\n* Creatinine \u2264 2.5 mg/dL OR creatinine clearance \u2265 30 mL/min\n* AST and ALT \\< 2.5 times upper limit of normal (ULN)\n* Total bilirubin \\< 1.2 times ULN\n* Prothrombin time (PT) and activated partial thromboplastin time (aPTT) \\< 1.5 times ULN\n\n  * Patients receiving warfarin or heparin therapy for a history of thrombosis, embolism, or other indication must have PT and/or aPTT within the accepted therapeutic ranges for those indications\n* Patients with a history of reactions to other liposomal drug formulations that are not due to the liposome itself may be eligible at the discretion of the investigator\n* No known HIV seropositivity\n* No known active hepatitis A, B, or C viral infection\n* No New York Heart Association class III or IV congestive heart failure\n* LVEF \u2265 45% by 2-D ECHO or MUGA\n* No acute ischemia or new conduction system abnormality by EKG\n* No conduction system abnormality (e.g., left bundle branch block) by EKG that would preclude the ability to detect new ischemic episodes\n* No myocardial infarction within the past 6 months\n* No significant comorbidity, such as poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that, in the opinion of the investigator, might compromise any aspect of the study\n* No uncontrolled infection\n\n  * Patients may have febrile episodes up to 38.5\u00b0C if these are felt to be due to tumor fever and the possibility of infection has been ruled out by evaluation\n* No prior hypersensitivity reaction to pegylated doxorubicin hydrochloride liposome or doxorubicin hydrochloride\n\n  * Patients with a history of reactions to other liposomal drug formulations and/or to the liposome itself, as opposed to the encapsulated agent, may be excluded at the discretion of the investigator\n\nPhase II\n\n* Female or male\n* Menopausal status not specified\n* Karnofsky performance status 70-100%\n* Life expectancy \u2265 3 months\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 3 months after completion of study therapy\n* ANC \u2265 1,500/mm\u00b3\n* Platelet count \u2265 100,000/mm\u00b3\n* Hemoglobin \u2265 9.0 g/dL\n* Creatinine \u2264 2.5 mg/dL (\u2264 200 \u00b5mol/L)\n* AST and ALT \u2264 2 times ULN\n* Alkaline phosphatase \u2264 2 times ULN (unless attributed to tumor)\n* Bilirubin \u2264 ULN\n* Cardiac ejection fraction \\> 50% by MUGA or 2-D ECHO\n* No clinical evidence of congestive heart failure\n* No New York Heart Association class II-IV cardiac disease\n* No myocardial infarction within the past 6 months\n* No uncontrolled angina\n* No severe uncontrolled ventricular arrhythmias\n* No evidence of acute ischemia or active conduction system abnormalities by EKG\n\n  * Any EKG abnormality at screening must be documented by the investigator as not medically relevant\n* No grade 2 peripheral neuropathy within the past 14 days\n* No significant comorbidity that would impair compliance with study therapy or interpretation of study results\n* No history of hypersensitivity reactions attributed to a conventional formulation of doxorubicin hydrochloride or the components of pegylated doxorubicin hydrochloride liposome\n* No hypersensitivity to bortezomib, boron, or mannitol\n* No serious medical or psychiatric illness likely to interfere with participation in this study\n\nPRIOR CONCURRENT THERAPY:\n\nPhase I (closed to accrual as of 10/15/2007)\n\n* More than 3 weeks since prior major surgery\n* More than 3 weeks since prior and no concurrent radiotherapy\n* More than 4 weeks since prior and no concurrent immunotherapy (i.e., interferon, interleukin, or other cytokine-based treatment)\n* More than 3 weeks since prior and no concurrent participation in another therapeutic clinical trial with an experimental drug\n* More than 3 weeks since prior and no other concurrent chemotherapy\n* No prior doxorubicin dose \\> 400 mg/m\u00b2\n* No other concurrent antineoplastic therapy\n\nPhase II\n\n* More than 6 months since prior anthracyclines\n* More than 14 days since other prior investigational drugs\n* No more than 300 mg/m\u00b2 of prior doxorubicin or 540 mg/m\u00b2 of prior epirubicin\n* No more than two prior chemotherapy regimens for metastatic disease\n* No other concurrent antineoplastic therapy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}